| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | 67,513.0 | 64,009.0 |
| Gross profit | 2,596.0 | 2,319.0 |
| Profit before tax | 688.0 | 598.0 |
| Net income | 554.0 | 450.0 |
| EPS (diluted, $ a share) | $2.38 | $1.88 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | +23.1% |
|---|---|
| Revenue, year on year | +5.5% |
| Gross margin | 3.8% |
| Operating margin | 1.1% |
10-Q filed with the SEC, NYSE: CAH. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Cardinal Health Inc: key numbers
- Share price
- $279.25Close, Nov 17
- Market cap
- $64.5B
- Shares outstanding
- 231.14MLatest SEC cover page
- Sector
- Trade & Services
- Industry
- Wholesale-Drugs, Proprietaries & Druggists' SundriesSIC 5122
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Cardinal Health Inc
All →Cardinal Health Shareholder Meeting
Cardinal Health held its 2026 Annual Meeting of Shareholders on November 12, 2026, where shareholders elected 11 directors to the board. Additionally, shareholders approved the executive compensation plan (say-on-pay) and ratified the appointment of Ernst & Young LLP as the independent auditor for the fiscal year ending June 30, 2027.
Cardinal Health Financial Results
Cardinal Health reported Q1 fiscal 2027 revenue of $67.5 billion, a 5% increase year-over-year, driven by brand and specialty pharmaceutical sales. Non-GAAP diluted EPS rose 28% to $3.26, leading the company to raise its full-year fiscal 2027 non-GAAP EPS guidance. The company also completed a $500 million share repurchase program during the quarter.
- Term
- Q1 2027
“Our results reflect a strong start to fiscal 2027 and demonstrate consistent execution against our strategic priorities. We continue to benefit from focused investments, disciplined operations and the strength of our diversified portfolio. Given this quarter's strong performance and our updated expectations for the remainder of the year, we are raising our fiscal 2027 non-GAAP EPS outlook.”
Jason Hollar, CEO of Cardinal Health
Cardinal Health Investor Meeting
Cardinal Health entered into a binding letter of intent to extend its pharmaceutical distribution agreements with CVS Health through June 2032. In connection with the extension, the company reaffirmed its fiscal year 2027 non-GAAP EPS guidance of $12.40 to $12.60 and its long-term growth targets.
- Counterparty
- CVS Health
- Term
- through June 2032